Senior Vice President - Regulatory, Quality and Technical Operations
Randy Brenner has over 20 years of pharmaceutical and regulatory experience in leading the development and registration of products across many different regions and therapeutic areas, including anti-infectives. Mr. Brenner comes to us from Shire where he was the Global Head of Regulatory Affairs at Shire Pharmaceuticals. At Shire he was responsible for all aspects of regulatory for a broad range of programs in multiple therapeutic areas and pharmaceutical technologies. He was a member of key executive leadership teams and helped contribute to the growth of Shire through critical programs and product approvals over the last three and a half years. Mr. Brenner joined Shire from Pfizer where he was Head of Regulatory Affairs for the Emerging Markets and Established Products Business Units. In this role he played an active part on the regional leadership teams and was responsible for the regulatory activities and staff leading the development, registration, launch, and life cycle of all of Pfizer's innovative products outside the United States and European Union as well as the Established Products business in all regions. Under his leadership many significant regulatory accomplishments were achieved ranging from the global expansion of Pfizer's programs to establishing important relationships and innovated approaches to development with key regulatory agencies in Asia, Latin America, and other key growth regions. Prior to Pfizer Randy spent 14 years at Wyeth Pharmaceuticals, where he held multiple senior regulatory positions. His leadership and regulatory capabilities contributed to the successful development, registration and launch of many new products (including Tygacil) and important life cycle expansions in many different therapeutic areas including those in the field of anti-infectives.
Vice President - Technical Operations
Jason Burdette has over 25 years experience in the pharmaceutical industry concentrated on formulation and process development, manufacturing, supply chain management and technical operations. He brings extensive experience in new product introduction of multiple products in both the US and international markets. Mr. Burdette joins us from Eagle Pharmaceuticals where he was the VP, Supply Chain. At Eagle he was responsible for supply chain management, procurement, distribution and new product introduction. Mr. Burdette joined Eagle from Shire Pharmaceuticals where he held various positions with increasing responsibility over his 10-year tenure. Including, VP Geographic Expansion Strategy and Planning, Interim Head of Product Strategy, Product Strategy Lead for Vyvanse, Adderall, and Equasym, Global Product Director, Supply Chain for the ADHD business. He was an active member of the supply chain leadership team and the international commercial team among other key executive leadership teams. Prior to Shire Pharmaceuticals, Mr. Burdette worked with aaiPharma, Elan Pharmaceuticals, Sandoz and Mylan Pharmaceuticals.
Senior Vice President - Business Development
Jeanne Jew joined Paratek in July 2015. Ms. Jew has more than 20 years of experience in business development, product planning and general management in the biotechnology industry. Prior to joining Paratek, Ms. Jew was Senior Vice President, Business Development of KaloBios Pharmaceutical where she was responsible for business development, strategic planning, and marketing. During her tenure at KaloBios, Ms. Jew was responsible for the execution and management of its partnership with Sanofi Pasteur, and played in key role in the IPO. From 2002-2007, Ms. Jew served as Vice President of Corporate Development of Onyx Pharmaceuticals, where she was responsible for all business development activities and commercial planning for Nexavar. Prior to Onyx Pharmaceuticals, Ms. Jew held business development positions at Coulter Pharmaceuticals and became Vice President, Business Development following the acquisition of Coulter Pharmaceutical by Corixa Corporation. Earlier in her career, Ms. Jew held business development positions at Scios, Inc. and Genentech, Inc. Ms. Jew holds a Bachelor of Arts in psychology from Wesleyan University and a Master of Business Administration from Cornell University.
Paul McGovern, M.D.
Vice President - Clinical and Medical Affairs
Paul McGovern, M.D. joined Paratek in February 2017 as a Vice President of Clinical and Medical Affairs. Prior to joining Paratek, Dr. McGovern worked in Global Clinical Development at Actelion Clinical Research as a Clinical Science Program Head for cadazolid, an antibiotic in late development for Clostridium difficile infection and as an Infectious Diseases expert for other anti-infective products in development. From 2006-2013, Dr. McGovern held positions in Medical and Clinical Affairs at Wyeth and Pfizer where he worked on the tigecycline late life-cycle strategy and activities including the benefit risk. Dr. McGovern has a B.S. from the University of Notre Dame and a M.D. from Northwestern University. He completed an Internal Medicine Residency and Infectious Diseases Fellowship at the University of Pennsylvania. Following the completion of his medical training, Dr. McGovern was a faculty member at the University of Pennsylvania prior to joining Wyeth in 2006.
Vice President - Information Technology
Raj Padmanabhan is our Vice President, Information Technology (IT), facilities and space planning and has served in this position since November, 2015. With more than 20 years of experience, Mr. Padmanabhan previously served as Senior Director, IT Architecture, Quality and Processes at Cubist Pharmaceuticals, a wholly owned subsidiary of Merck. During his eight-year tenure at Cubist, Mr. Padmanabhan built Information Technology infrastructure to scale business operations and support the growth of the business including successful launch of two new anti-infective products in US and international markets and successful relaunch of two commercial products in US market. Mr. Padmanabhan led several leadership task forces to increase productivity and ensure compliance with federal regulations. Prior to Cubist, Mr. Padmanabhan was Associate Director, Business and Integration Service at Biogen where he implemented global systems to support compliance with federal regulations, improve productivity and reduce costs. Raj Padmanabhan has a Bachelor of Engineering degree in Computer science and Engineering from University of Madras and a Masters in Business Administration from Babson College.
Senior Vice President - Human Resources
Regina joined Paratek Pharmaceuticals as Senior Vice President of Human Resources in September 2015. She most recently served as Senior Vice President, Human Resources at Myriant Corporation, a global Biotech Chemical company. Over the past five years at Myriant, Regina led initiatives aimed at creating an optimal corporate culture for employee recruitment and retention, such as reward systems, benefits, professional development and other policies. In this capacity, Regina also designed and introduced a branded Mission and Core Values initiative for the newly appointed CEO to define organizational direction and enhance employee engagement. Prior to her experience at Myriant, Regina served as Vice President, Human Resources for Mascoma Corporation, a Biotech Energy company. In this role, she focused on strategies to optimize corporate culture and organizational effectiveness, led the CEO search and was responsible for facilitating a successful CEO Leadership transition. Regina was also Senior Vice President, Human Resources at Sepracor Pharmaceutical, Inc., now Sunovion Pharmaceuticals where in her ten year tenure she led HR Organizational initiatives to scale up the company from a 100 person research based organization to a commercial entity with over 2,000 employees. Among her many responsibilities, she crafted strategy for four national sales force expansions to source and hire more than 1,800 sales reps for the hospital-based and community-focused field salesforce. She is a magna cum laude graduate from Suffolk Universities’ Sawyer School of Business and also earned a Master of Arts in Human Resources Management from Framingham State College.
Susan Perkins J.D.
Vice President - Intellectual Property
Susan Perkins, J.D., prior to joining Paratek, Ms. Perkins has been sole in-house patent counsel for multiple start-up biotechnology companies, managing portfolios for clinical stage and preclinical drug candidates while building platform technology IP. Most recently, Ms. Perkins was Head of Intellectual Property at Aileron Therapeutics, a leader in Stapled Peptide therapeutics. Prior to that she led IP at Avila Therapeutics (acquired by Celgene), Syntonix Pharmaceuticals (acquired by Biogen Idec) and Leukosite (acquired by Millennium Pharmaceuticals for which Ms. Perkins continued as patent counsel). Before going in-house, Ms. Perkins was associated with the law firm of Campbell & Flores in San Diego, CA. She began as a Patent Examiner with the U.S. Patent & Trademark Office. She holds a J.D. with Honors from the George Washington University, which included an externship with the Honorable Randall Radar of the U.S. Court of Appeals for the Federal Circuit. Ms. Perkins holds an advanced degree in chemistry from the University of North Carolina, and graduated Summa Cum Laude from UMass-Amherst.
Senior Vice President - Clinical Development & Clinical Operations
Evan Tzanis joined Paratek in September 2014 as Vice President of Clinical Development to oversee clinical development strategic and operational deliverables including the design/oversight of clinical trials, biometrics and regulatory affairs. Mr. Tzanis brings over 20 years of global drug development experience in all aspects of clinical, operational, and regulatory processes. Prior to joining Paratek, Mr. Tzanis served as Head of Clinical Operations and Biometrics at Endo Pharmaceuticals where he also had leadership responsibility in clinical and project management. During his tenure with Endo, Mr. Tzanis was responsible for a number of late stage development programs, including BEMA® Buprenorphine, which successfully completed Phase 3. Prior to joining Endo, Mr. Tzanis was the Global Clinical Program Leader at Wyeth and Pfizer for a number of successful new products on the market today to treat a range of CNS disorders including panic disorder, major depressive disorder, sleep and other medical conditions, including opioid induced constipation and rheumatoid arthritis.